



# BLADDER17®

## Non-Invasive Bladder Cancer Detection

Early detection of bladder cancer is vital for improved patient outcomes, especially in cases of recurrence. Traditional diagnostic procedures have been invasive and expensive, often causing physical and emotional distress for patients who require frequent monitoring. Fortunately, non-invasive tests like Bladder17® have emerged as effective alternatives, providing quicker and more comfortable results. These tests not only simplify the diagnostic process but also enhance the overall patient experience and quality of life. They play a crucial role not only in initial detection but also in monitoring for recurrence, ensuring that early detection remains accessible and less burdensome for individuals dealing with bladder cancer and its potential recurrence.



### About Bladder17®

- 100% Negative Predictive Value (NPV)\*
- Non-Invasive Urine Test
- High sensitivity and NPV\*\*
- Detects both Low and High grade
- Reimbursed by Applicable CPT Codes
- Effective surveillance for monitoring recurrence

### Risk Stratification\*

- Negative Cytology/Negative Bladder17® → No to Low Risk of Bladder Cancer
- Atypical Cytology/Negative Bladder17® → No to Low Risk of Bladder Cancer
- Negative Cytology/High Bladder17® Expression → Standard Diagnostic Workup is Recommended
- Atypical Cytology/High Bladder17® Expression → Standard Diagnostic Workup is Recommended

\*Babu et al. 2019. Modern Pathology. Vasdev et al. 2020. Babu et al 2021

\*\*Developed by a panel of Urology Specialists and Scientific Advisors

For more information, please contact us at: [cs@emeritusdx.com](mailto:cs@emeritusdx.com)

**EmeritusDX**  
Together, We Save Lives

800.959.2846

[www.emeritusdx.com](http://www.emeritusdx.com)

**Clinical Utility**

**100% Negative Predictive Value**  
**Non-Invasive**  
**Monitors For Recurrence**  
**High Risk Group**  
(Smokers, Chemical Exposure, Veterans, Family History)



EDX-B17 0824